Peptide targeted radiotherapy – a promising new approach to cancer therapy.
Our targeted therapy has been widely validated in clinical studies as well as in routine clinical use in Europe. Learn More
News from Andarix
- Andarix Pharmaceuticals CEO to Groundbreaking Targeted Peptide Therapy at Clinical Trials Conference
October 23, 2024 Innovative Approach to Rare Cancer Treatment Attracts Attention from Industry Leaders and Patient Groups Boston — Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for rare cancers, announced today that its CEO, Chris Adams will present the two-day conference on outsourcing clinical… Read more: Andarix Pharmaceuticals CEO to Groundbreaking Targeted Peptide Therapy at Clinical Trials Conference - Andarix Pharmaceuticals CEO to Chair Rare Disease Clinical Trials Conference
September, 2023 Andarix Pharmaceuticals CEO to Chair Rare Disease Clinical Trials Conference Boston — Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for rare cancers announced today that its CEO, Chris Adams will Chair the two days conference on rare diseases. The conference will include… Read more: Andarix Pharmaceuticals CEO to Chair Rare Disease Clinical Trials Conference - Andarix Pharmaceuticals to Lead Panel Discussion at Clinical Trial Conference
July 11, 2023 Conference Highlights Key Features of Successful Clinical Trial Management SOMERVILLE, MA — July 11, 2023 — Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will lead a panel discussion composed of industry experts on the key… Read more: Andarix Pharmaceuticals to Lead Panel Discussion at Clinical Trial Conference